Addison Advisors’s NovoCure NVCR Stock Holding History

Addison Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200	Closed	-$2.18K	–	904
2026 Q1	$2.18K	Hold	200	–	–	﹤0.01%	823
2025 Q4	$2.59K	Hold	200	–	–	﹤0.01%	767
2025 Q3	$2.58K	Hold	200	–	–	﹤0.01%	764
2025 Q2	$3.56K	Hold	200	–	–	﹤0.01%	729
2025 Q1	$3.56K	Hold	200	–	–	﹤0.01%	705
2024 Q4	$5.96K	Hold	200	–	–	﹤0.01%	645
2024 Q3	$3.13K	Hold	200	–	–	﹤0.01%	708
2024 Q2	$3.43K	Hold	200	–	–	﹤0.01%	665
2024 Q1	$3.13K	Hold	200	–	–	﹤0.01%	604
2023 Q4	$2.99K	Hold	200	–	–	﹤0.01%	602
2023 Q3	$3.23K	Hold	200	–	–	﹤0.01%	566
2023 Q2	$8.3K	Hold	200	–	–	﹤0.01%	494
2023 Q1	$12K	Hold	200	–	–	0.01%	443
2022 Q4	$14.7K	Hold	200	–	–	0.01%	406
2022 Q3	$15K	Hold	200	–	–	0.01%	392
2022 Q2	$14K	Hold	200	–	–	0.01%	404
2022 Q1	$17K	Buy	+200	New	+$14.7K	0.01%	416

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Addison Advisors's NVCR Position: Q2 2026 in Review

Addison Advisors sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 200 shares — an estimated $2.18K sold.

Addison Advisors first reported a position in NVCR in Q1 2022 and held it in 17 quarters. The position peaked at $17K in Q1 2022. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Addison Advisors reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Addison Advisors sold 200 NovoCure shares in Q2 2026, an estimated $2.18K.
Addison Advisors first reported a position in NovoCure in Q1 2022 and held it in 17 quarters.
Addison Advisors's NovoCure position peaked at $17K in Q1 2022.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.